New vaccine tested to protect vulnerable kids from serious infections
NCT ID NCT07247188
Summary
This study aims to see if a new 21-valent pneumococcal vaccine (PCV21) is safe and helps the body build protective antibodies in children and teens with sickle cell disease. It will compare the new vaccine to an already licensed vaccine. About 100 participants aged 2 to 17 will receive a single dose and be followed for up to 6 months to monitor their response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site # 8400006
RECRUITINGAtlanta, Georgia, 30310, United States
Conditions
Explore the condition pages connected to this study.